Breast cancer antiestrogen resistance 3 (BCAR3)

Breast cancer antiestrogen resistance 3 (BCAR3) is a cytoplasmic adaptor protein and a member of the NSP (novel SH2-containing protein) family, characterized by an N-terminal Src homology 2 (SH2) domain and a C-terminal domain with homology to guanine nucleotide exchange factors (GEFs) [1, 4]. Originally identified for its role in conferring resistance to antiestrogen therapies like tamoxifen, BCAR3 functions as a molecular scaffold that coordinates signaling between growth factor receptors (such as MET, EGFR, and the insulin receptor) and the actin cytoskeleton [5, 6]. It binds tightly to BCAR1 (p130Cas), a key regulator of focal adhesions, to activate downstream effectors like Rac1, Cdc42, and Src, thereby driving cell proliferation, migration, and invasion [7, 8]. High expression or hypomethylation of BCAR3 is associated with poor clinical outcomes in several malignancies, including triple-negative breast cancer, head and neck squamous cell carcinoma, and thyroid cancer [9, 10, 11]. While no direct small-molecule inhibitors are currently approved, BCAR3 is an active target for research into overcoming drug resistance, with experimental approaches including peptide-based vaccines and disruptors of the BCAR1-BCAR3 complex [7, 8].

Other names

NSP2SH2D3BAND-34MIG7Migration inducting gene-7Novel SH2-containing protein 2Breast cancer anti-estrogen resistance protein 3NSP family adaptor protein

BCAR3 functions as a signaling scaffold that promotes antiestrogen resistance by activating alternative growth and survival pathways, such as PI3K/AKT and MAPK/ERK, and by regulating cytoskeletal dynamics through its interaction with BCAR1 (p130Cas); experimental therapies aim to disrupt these protein-protein interactions or utilize vaccines to target BCAR3-expressing cells.